公开(公告)号：TWI516262B

公开(公告)日：2016-01-11

申请号：TW100111767

申请日：2011-04-06

Applicant: 健康網路大學 ,  UNIVERSITY HEALTH NETWORK

Inventor： 山普森 彼德 布蘭特 ,  SAMPSON, PETER BRENT ,  劉勇 ,  LIU, YONG ,  李詩韻 ,  LI, SZE-WAN ,  佛瑞斯 布萊恩T ,  FORREST, BRYAN T. ,  保羅斯 漢茲W ,  PAULS, HEINZ W. ,  艾德華 路易斯G ,  EDWARDS, LOUISE G. ,  菲爾 米克洛斯 ,  FEHER, MIKLOS ,  帕特 那倫卓 庫馬B ,  PATEL, NARENDRA KUMAR B. ,  勞夫 拉朵斯洛 ,  LAUFER, RADOSLAW ,  潘國華 ,  PAN, GUOHUA

IPC: A61K31/404 ,  A61K31/416 ,  C07D403/10 ,  A61P35/00

CPC classification number: C07D403/10 ,  A61K31/5377 ,  A61K45/06 ,  C07D231/56 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14

公开(公告)号：WO2023283732A1

公开(公告)日：2023-01-19

申请号：PCT/CA2022/051087

申请日：2022-07-12

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： ZHENG, Gang ,  CHEN, Juan ,  HO, Tiffany ,  BU, Jiachuan ,  DING, Lili

IPC: A61K47/54 ,  A61K9/51 ,  A61K41/00 ,  A61K47/69 ,  A61K49/00 ,  A61K51/04 ,  A61K51/12

Abstract: There is described herein a bilayer nanovesicle comprising porphyrin-phospholipid conjugate and a chelator-fatty acid conjugate; wherein the chelator-fatty acid conjugate comprises an aminopolycarboxylic acid conjugated to a single chain fatty acid; and the porphyrin-phospholipid conjugate comprises one porphyrin, porphyrin derivative or porphyrin analog covalently attached to a lipid side chain, preferably at the sn-1 or the sn-2 position, of one phospholipid.

公开(公告)号：WO2022251948A1

公开(公告)日：2022-12-08

申请号：PCT/CA2022/050334

申请日：2022-03-08

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： LIU, Mingyao ,  KESHAVJEE, Shafique ,  CYPEL, Marcelo

IPC: A01N1/02

Abstract: Provided is a lung preservation composition comprising a non-carbonic buffered nutrient media, preferably a phosphate buffered nutrient media, and a dextran, optionally Dextran 40 and and optionally prostaglandin E1 (PGE1), and optionally at least one of alpha 1 antitrypsin (A1AT), an impermeant, optionally raffinose, an antioxidant, optionally glutathione, and necrostatin-1. Also described is a method of preserving a lung prior to and/or during transplant using said lung preservation composition, and kits comprising one or more components of the lung preservation composition.

公开(公告)号：WO2022187968A1

公开(公告)日：2022-09-15

申请号：PCT/CA2022/050363

申请日：2022-03-11

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： BROKX, Richard ,  MASON, Jacqueline M. ,  BRAY, Mark Robert ,  DUNCAN, Gordon S.

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  C12N15/13 ,  C12P21/08

Abstract: The invention provides novel anti-LILR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation.

公开(公告)号：WO2022087719A1

公开(公告)日：2022-05-05

申请号：PCT/CA2021/051470

申请日：2021-10-19

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HAROON, Nigil ,  NAKAMURA, Akihiro

IPC: A61K39/395 ,  A61K31/423 ,  A61P19/00 ,  C07D263/58 ,  C07K16/24

Abstract: Provided are methods of treating SpA, uses for treating SpA and compositions for treating SpA. The methods involve administering a MIF inhibitor to a subject in need thereof. The MIF inhibitor can be a compound or an anti-MIF antibody.

公开(公告)号：WO2022051847A1

公开(公告)日：2022-03-17

申请号：PCT/CA2021/051239

申请日：2021-09-08

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： FEHLINGS, Michael G. ,  KHAZAEI, Mohammad ,  AHUJA, Christopher S.

IPC: C12N5/0797 ,  A61K35/30 ,  A61P25/00 ,  A61P25/28 ,  C12N5/079 ,  C12N5/06

Abstract: Provided herein are methods of producing spNPCs from iPSCs or NPCs, cell populations, compositions comprising cell populations, and uses of spNPCs made using the methods described. The method can comprise: a. obtaining unpatterned NPCs, the unpatterned NPCs expressing neuroectodermal markers including Pax6 and Sox1; b. priming the unpatterned NPCs of step a; and c. patterning the primed unpatterned NPCs to produce spNPCS.

公开(公告)号：WO2021203190A1

公开(公告)日：2021-10-14

申请号：PCT/CA2021/050452

申请日：2021-04-05

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： FLETCHER, Graham ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: A61K31/5377 ,  A61K39/395 ,  A61P35/00 ,  C07D413/10 ,  C07K16/28

Abstract: Provided herein are methods of treating triple negative breast cancer using an effective amount of Compound (I) represented by the formula: or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor, wherein the checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor. Uses of an effective amount of Compound [I] and an effective amount of an immune checkpoint inhibitor, wherein the checkpoint inhibitor is a PD-1inhibitor or a PD-L1 inhibitor for treating triple negative breast cancer are also provided herein.

公开(公告)号：WO2021022367A1

公开(公告)日：2021-02-11

申请号：PCT/CA2020/051062

申请日：2020-08-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： LUPIEN, Mathieu ,  HAIBE-KAINS, Benjamin ,  MADANI TONEKABONI, Seyed Ali

IPC: G16B20/30 ,  C12Q1/6869 ,  G16B15/30

Abstract: The present disclosure relates to the development of methods for identifying cis-regulatory elements. Also disclosed herein are various methods including for example determining the tissue of origin of a biological sample, prognosis of a patient diagnosed with a cancer and their response to treatments.

公开(公告)号：WO2021019474A1

公开(公告)日：2021-02-04

申请号：PCT/IB2020/057174

申请日：2020-07-29

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  SUGATA, Kenji ,  GUO, Tingxi

IPC: C07K14/74 ,  A61K38/17 ,  A61P31/00 ,  A61P35/00 ,  C12N15/12

Abstract: The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DR beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

公开(公告)号：WO2021019473A1

公开(公告)日：2021-02-04

申请号：PCT/IB2020/057173

申请日：2020-07-29

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  SUGATA, Kenji

IPC: C07K14/74 ,  A61K38/17 ,  A61P35/00 ,  C12N15/12 ,  G01N33/567 ,  C12N5/07

Abstract: The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DQ beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.